Valuation check: 6986.TWO's profit margin is 37.74%, above the Healthcare sector average of 17.63%.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2026
Trailing 12 months ending Jun 2026
As of the most recent data (June 2026), 6986.TWO shows a profit margin of 37.74%. That compares with 43.65% in the prior-year period — down 13.5% year over year. That is above the Healthcare sector average of 17.63%. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, 6986.TWO's profit margin is now 37.74% (was 43.65%) — a 13.5% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether HeXun Biosciences , Ltd. is outperforming or lagging.
The Healthcare sector average profit margin is about 17.63%. HeXun Biosciences , Ltd. is at 37.74%, which is higher that average. That is roughly 114.1% above the sector mean. Use the comparison chart on this page to see how 6986.TWO stacks up against individual peers as well.
That compares with 43.65% in the prior-year period — down 13.5% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare HeXun Biosciences , Ltd. with peers to see if the move is company-specific or sector-wide.
Besides this profit margin page, Stockcircle has HeXun Biosciences , Ltd.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently 37.74%) with ownership activity and broader fundamentals.